Market Cap 6.00B
Revenue (ttm) 0.00
Net Income (ttm) -255.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 2,834,200
Avg Vol 3,461,622
Day's Range N/A - N/A
Shares Out 142.38M
Stochastic %K 73%
Beta 0.50
Analysts Strong Sell
Price Target $48.91

Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The c...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 945 5576
Address:
275 Wyman Street, 3rd Floor, Waltham, United States
RunnerSignals
RunnerSignals Dec. 12 at 9:45 PM
Morning Red Turns Afternoon Green $COGT $STIM $VERA $ANVS stumbled out the gate but soared into the close. market warriors showing how to flip the script in style
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:19 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $40.01, with an RSI of 70.83 indicating overbought conditions. The stock is above its 30-day moving average (MA30) of 32.03 and 50-day moving average (MA50) of 25.54, showing strong bullish momentum. However, the high of $43.73 in the last 60 days suggests potential resistance ahead. Directional Bias: Given the high RSI and proximity to the 60D high, caution is warranted. A pullback may occur, but if it holds above MA30, bullish sentiment could continue. Trade Plan: - Suggested Entry: $40.00 - Stop Loss: $37.00 (3% below entry) - Take Profit Targets: 1. $42.00 (5% gain) 2. $43.00 (7.5% gain) 3. $46.00 (15% gain, 17% ROI) Monitor the stock closely for signs of reversal or continuation. Adjust stop loss to protect gains as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BioBum
BioBum Dec. 11 at 11:39 PM
$VTGN $COGT had a Friday morning PR. Give it to us
1 · Reply
aristocks
aristocks Dec. 11 at 7:04 PM
$COGT lets go! moving higher! Added more and looking for really short term price target of 44$ As usual, will sell most of my position for a short (big) trade and keep around 100 shares to: 1. keep riding the rollercoster 2. keep an eye on the stock in case it gets buyout or Institutions interest! Not financial advice. Do your DD.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:22 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $38.53, showing strong upward momentum. The RSI at 69.66 indicates it's nearing overbought territory, suggesting caution. However, the stock is above its 30-day (30.46) and 50-day (24.53) moving averages, signaling bullish momentum. Directional Bias: The recent price action is near the 60-day high of 43.73, indicating potential resistance. The strong performance relative to the moving averages supports a bullish outlook, but the high RSI suggests a pullback could occur. Trade Plan: - Suggested Entry: $38.53 - Stop Loss: $36.00 (approx. 6.5% risk) - Take Profit Targets: 1. $40.00 (4% gain) 2. $42.00 (9.6% gain) 3. $45.00 (17% gain) This plan provides a clear risk-reward structure with a potential 17% ROI at the third target. Monitor the RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
matmasr
matmasr Dec. 9 at 5:55 PM
These are year to date Moon Shot Alerts from a scanner I created using TradeIdeas. The alert triggers in $10-$12 Range. Most of the stocks on this list have seen double and tripple growth from the alert like $NEGG $COGT and $REZI. Get your TradeIdeas Subscribption at Grab your copy at https://go.trade-ideas.com/SH15b and use code "matmasr" for 15% off.
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:48 PM
@CarlosLacombe $COGT Cogent released full SUMMIT data and positive APEX top-line results for bezuclastinib, showing strong efficacy across SM populations. An AdvSM NDA is planned for 1H26.
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:13 PM
@CarlosLacombe $COGT Cogent reported strong SUMMIT and APEX data for bezuclastinib, with significant symptom and biomarker reductions. The company plans an AdvSM NDA in 1H26.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:11 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $39.97, with a strong RSI of 77.51 indicating overbought conditions. However, the stock is above both the 30-day MA of 29.71 and the 50-day MA of 24.03, suggesting bullish momentum. The recent high of $43.73 provides a resistance level to watch. Directional Bias: The strong RSI indicates potential for a pullback, but the price is still trending upward above key moving averages. Given the high-low range of $11.6 to $43.73, there is room for growth if momentum continues. Trade Plan: - Suggested Entry: $39.97 - Stop Loss: $36.00 (approximately 10% below entry) - Take Profit Targets: 1. $42.00 (5% gain) 2. $43.00 (7.5% gain) 3. $46.00 (15% gain) Target 3 provides a potential ROI of over 17%. Monitor RSI for signs of reversal and adjust stop loss accordingly. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:17 PM
Needham updates rating for Cogent Biosciences ( $COGT ) to Hold.
0 · Reply
Latest News on COGT
3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 10 days ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

IBB TVTX XBI CYTK


Why Is Cogent Biosciences Stock Trading Higher On Monday?

Jul 7, 2025, 9:22 AM EDT - 5 months ago

Why Is Cogent Biosciences Stock Trading Higher On Monday?


Cogent Biosciences Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 7 months ago

Cogent Biosciences Reports First Quarter 2025 Financial Results


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 11 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN JAZZ ONC XBI ZYME


RunnerSignals
RunnerSignals Dec. 12 at 9:45 PM
Morning Red Turns Afternoon Green $COGT $STIM $VERA $ANVS stumbled out the gate but soared into the close. market warriors showing how to flip the script in style
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:19 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $40.01, with an RSI of 70.83 indicating overbought conditions. The stock is above its 30-day moving average (MA30) of 32.03 and 50-day moving average (MA50) of 25.54, showing strong bullish momentum. However, the high of $43.73 in the last 60 days suggests potential resistance ahead. Directional Bias: Given the high RSI and proximity to the 60D high, caution is warranted. A pullback may occur, but if it holds above MA30, bullish sentiment could continue. Trade Plan: - Suggested Entry: $40.00 - Stop Loss: $37.00 (3% below entry) - Take Profit Targets: 1. $42.00 (5% gain) 2. $43.00 (7.5% gain) 3. $46.00 (15% gain, 17% ROI) Monitor the stock closely for signs of reversal or continuation. Adjust stop loss to protect gains as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BioBum
BioBum Dec. 11 at 11:39 PM
$VTGN $COGT had a Friday morning PR. Give it to us
1 · Reply
aristocks
aristocks Dec. 11 at 7:04 PM
$COGT lets go! moving higher! Added more and looking for really short term price target of 44$ As usual, will sell most of my position for a short (big) trade and keep around 100 shares to: 1. keep riding the rollercoster 2. keep an eye on the stock in case it gets buyout or Institutions interest! Not financial advice. Do your DD.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:22 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $38.53, showing strong upward momentum. The RSI at 69.66 indicates it's nearing overbought territory, suggesting caution. However, the stock is above its 30-day (30.46) and 50-day (24.53) moving averages, signaling bullish momentum. Directional Bias: The recent price action is near the 60-day high of 43.73, indicating potential resistance. The strong performance relative to the moving averages supports a bullish outlook, but the high RSI suggests a pullback could occur. Trade Plan: - Suggested Entry: $38.53 - Stop Loss: $36.00 (approx. 6.5% risk) - Take Profit Targets: 1. $40.00 (4% gain) 2. $42.00 (9.6% gain) 3. $45.00 (17% gain) This plan provides a clear risk-reward structure with a potential 17% ROI at the third target. Monitor the RSI and price action closely for adjustments. https://privateprofiteers.com
0 · Reply
matmasr
matmasr Dec. 9 at 5:55 PM
These are year to date Moon Shot Alerts from a scanner I created using TradeIdeas. The alert triggers in $10-$12 Range. Most of the stocks on this list have seen double and tripple growth from the alert like $NEGG $COGT and $REZI. Get your TradeIdeas Subscribption at Grab your copy at https://go.trade-ideas.com/SH15b and use code "matmasr" for 15% off.
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:48 PM
@CarlosLacombe $COGT Cogent released full SUMMIT data and positive APEX top-line results for bezuclastinib, showing strong efficacy across SM populations. An AdvSM NDA is planned for 1H26.
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:13 PM
@CarlosLacombe $COGT Cogent reported strong SUMMIT and APEX data for bezuclastinib, with significant symptom and biomarker reductions. The company plans an AdvSM NDA in 1H26.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:11 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $39.97, with a strong RSI of 77.51 indicating overbought conditions. However, the stock is above both the 30-day MA of 29.71 and the 50-day MA of 24.03, suggesting bullish momentum. The recent high of $43.73 provides a resistance level to watch. Directional Bias: The strong RSI indicates potential for a pullback, but the price is still trending upward above key moving averages. Given the high-low range of $11.6 to $43.73, there is room for growth if momentum continues. Trade Plan: - Suggested Entry: $39.97 - Stop Loss: $36.00 (approximately 10% below entry) - Take Profit Targets: 1. $42.00 (5% gain) 2. $43.00 (7.5% gain) 3. $46.00 (15% gain) Target 3 provides a potential ROI of over 17%. Monitor RSI for signs of reversal and adjust stop loss accordingly. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:17 PM
Needham updates rating for Cogent Biosciences ( $COGT ) to Hold.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 8 at 2:07 PM
$COGT $AVGO $CRWV $MRVL $TSLA PRE-MARKET MOVERS: Currently Higher: - Kymera Therapeutics (KYMR) up 35.9% after reporting clinical results from the BroADen Phase 1b atopic dermatitis clinical trial of KT-621 - Cogent Biosciences (COGT) up 12.6% after announcing results of APEX trial of bezuclastinib - Confluent (CFLT) up 29.4% after entering into a definitive agreement under which IBM (IBM) will acquire all of the issued and outstanding common shares of the company for $31 per share - Broadcom (AVGO) up 3.5% after The Information reported Microsoft (MSFT) is in talks to design custom chips with Broadcom, switching its business from Marvell (MRVL) Currently Lower: - Marvell (MRVL) down 7.1% after the report that Microsoft (MSFT) is in talks to design custom chips with Broadcom, switching its business from the company - CoreWeave (CRWV) down 4.1% after $2B convertible debt offering - Agios Pharmaceuticals (AGIO) down 1.2% after announcing that the FDA has not yet issued a regulatory decision on the supplemental new drug application for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains under active review - Tesla (TSLA) down 1.4% after Morgan Stanley downgraded the stock to Equal Weight from Overweight with a price target of $425, up from $410, as a new analyst took over coverage - ITT (ITT) down 1.8% after 7M share common stock offering
1 · Reply
Quantumup
Quantumup Dec. 8 at 1:51 PM
Raymond James reiterated $COGT Strong Buy/$60 BPMC - $SNY $PFE $GSK $OPHLY Raymond James said: Remain Strong Buy rated on COGT shares after full SUMMIT data this weekend at ASH solidified bezuclastinib's efficacy advantage over competitor Ayvakit in non-advanced systemic mastocytosis (NonAdvSM). While SUMMIT was top lined last July, we got additional details around reduction of serum tryptase, bone marrow mast cell burden and circulating KIT p.D816V VAF that we think will contribute to the strong symptom score reduction advantage we've known since July. Coupling this with three-year data on Ayvakit that shows a modest improvement in total symptom score over time, we continue to believe bezuclastinib will compete for treatment naïve patients right out of the gate starting next year after approval and launch in NonAdvM. We continue to model bezuclastinib revenue in NonAdvSM of $170.5M, $260.9M, $487.9M, and $678.6M for FY27-FY30, respectively.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 8 at 1:40 PM
$COGT (+8.6% pre) Cogent Biosciences reports positive APEX trial results for bezuclastinib - SI https://ooc.bz/l/86607
0 · Reply
eddymaldives
eddymaldives Dec. 8 at 1:09 PM
$COGT LFG ! Give me 50
0 · Reply
HahaYouSUCK
HahaYouSUCK Dec. 8 at 12:46 PM
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 7 at 1:29 AM
people asking about $COGT just watch H% get low like shown here
0 · Reply
justiceforb_85
justiceforb_85 Dec. 7 at 1:19 AM
$COGT outstanding data for bezuclastinib. Hope the market reacts positively to this news.
0 · Reply
ms0632
ms0632 Dec. 7 at 12:24 AM
$COGT are all those Dec $50 calls that were bought up last week going to pay on Monday based on the supplemental positive results?
0 · Reply
SnoopDawg
SnoopDawg Dec. 6 at 11:54 PM
$COGT supplemental data from ash today looks good.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:10 AM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $39.31, showing strong momentum but is in overbought territory with an RSI of 77.24. The stock is above its 30-day MA of 28.08 and 50-day MA of 23.01, indicating a bullish trend. However, caution is warranted due to the high RSI, suggesting a potential pullback. Directional Bias: The bullish trend is supported by the stock's position above key moving averages. The recent high of $41.27 indicates potential resistance, while the low of $11.6 provides a solid support level. Trade Plan: - Suggested Entry: $39.31 - Stop Loss: $36.00 (approximately 8% below entry) - Take Profit Targets: 1. Target 1: $41.00 (4.3% gain) 2. Target 2: $43.00 (9.3% gain) 3. Target 3: $46.00 (17% gain) Monitor the trade closely, especially given the current RSI levels. Adjust stop loss as necessary to protect gains. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
QuantInsider
QuantInsider Dec. 6 at 1:17 AM
$COGT seeing some interesting action Five-day call flow is heavy with 29x volume growth and $880K in ask-side sweeps on InsiderFinance But the stock is down 4.46% this week so it's still a tough tape Treat this bullish flow as speculative unless we get a confirmed intraday reversal Otherwise the downtrend might keep rolling Watch the charts closely
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:45 PM
Actionable Trade Alert for $COGT: Market Context: $COGT is currently trading at $39.31, showing strong momentum but is in overbought territory with an RSI of 77.24. The stock is above its 30-day MA of 28.08 and 50-day MA of 23.01, indicating a bullish trend. However, caution is warranted due to the high RSI, suggesting a potential pullback. Directional Bias: The bullish trend is supported by the stock's position above key moving averages. The recent high of $41.27 indicates potential resistance, while the low of $11.6 provides a solid support level. Trade Plan: - Suggested Entry: $39.31 - Stop Loss: $36.00 (approximately 8% below entry) - Take Profit Targets: 1. Target 1: $41.00 (4.3% gain) 2. Target 2: $43.00 (9.3% gain) 3. Target 3: $46.00 (17% gain) Monitor the trade closely, especially given the current RSI levels. Adjust stop loss as necessary to protect gains. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply